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Cognitive deficits in brain tumors are generally thought to be relatively mild and non-
specific, although recent evidence challenges this notion. One possibility is that cognitive
screening tools are being used to assess cognitive functions but their sensitivity to detect
cognitive impairment may be limited. For improved sensitivity to recognize mild and/or focal
cognitive deficits in brain tumors, neuropsychological evaluation tailored to detect specific
impairments has been thought crucial.This study investigates the sensitivity of a cognitive
screening tool, the Montreal Cognitive Assessment (MoCA), compared to a brief but tai-
lored cognitive assessment (CA) for identifying cognitive deficits in an unselected primary
brain tumor sample (i.e., low/high-grade gliomas, meningiomas). Performance is compared
on broad measures of impairment: (a) number of patients impaired on the global screening
measure or in any cognitive domain; and (b) number of cognitive domains impaired and
specific analyses of MoCA-Intact and MoCA-Impaired patients on specific cognitive tests.
The MoCA-Impaired group obtained lower naming and word fluency scores than the MoCA-
Intact group, but otherwise performed comparably on cognitive tests. Overall, based on
our results from patients with brain tumor, the MoCA has extremely poor sensitivity for
detecting cognitive impairments and a brief but tailored CA is necessary. These findings
will be discussed in relation to broader issues for clinical management and planning, as
well as specific considerations for neuropsychological assessment of brain tumor patients.
Keywords: neurocognitive deficits, brain tumor, cognitive screening, neuropsychology, brief cognitive assessment,
MoCA
INTRODUCTION
Cognitive function is an independent prognostic factor in the
survival of glioma patients (1, 2). For brain tumors, cognitive
assessment (CA) can inform clinicians of areas to target for neu-
rorehabilitation (3), monitor progress to facilitate decision making
about further intervention (4), and if there has been a decline in
cognitive function, address the question of whether the tumor has
recurred or progressed (3). In addition, a CA is able to address
the question of whether subtle alterations in cognitive function
are significant or not, particularly when monitoring slow-growing
low-grade gliomas (4). Assessment of cognitive status can be
undertaken with a brief cognitive screen or by a longer formal neu-
ropsychological evaluation. Cognitive screening is typically used
in acute states, at bedside, hence the focus of our study is to identify
whether a brief CA can be tolerated and completed in a relatively
acute state (post-surgery but <3 months) and, if so, whether this
yields better results in terms of detecting cognitive deficits.
Cognitive screening tools are popular but their sensitivity to
cognitive impairment in general, and specifically for brain tumor
patients, has been questioned (4). One reason may be that brain
tumor-associated cognitive deficits have been thought to be rela-
tively mild and non-specific (5), although this has recently been
challenged (6). It is unsurprising that severity and specificity of
cognitive deficits in brain tumor patients has been debated as
prevalence rates vary from 29 to 91%. This variability may depend
on several factors including time of assessment (pre- or post-
surgery), tumor grade, treatments (radiation, chemotherapy), and
lesion location (7). However, the main reason for this variability
may be the method used to assess cognitive functions. For example,
in one study, few patients with low-grade gliomas showed cognitive
deterioration when screened with the mini-mental state exami-
nation (MMSE) (8), irrespective of radiation treatment (9). By
contrast, Tucha and colleagues (10) investigated cognitive function
with neuropsychological tests and reported that 91% of patients
with frontal or temporal tumors were impaired in at least one cog-
nitive domain. In this study, we aimed to investigate the most effec-
tive and efficient method of detection of cognitive impairments in
the acute period following tumor resection by directly comparing
a cognitive screening tool with a brief but domain-specific CA.
Cognitive screening tools have the advantage of brevity and
simplicity of administration. The main question, however, is
whether these tools are sensitive to detect abnormalities. In the last
decade, the Montreal Cognitive Assessment (MoCA) (11) screen-
ing tool has been increasingly favored over the MMSE as it has
been shown to have greater sensitivity for detecting cognitive dys-
function. This has been shown in patients with brain tumors (12)
and brain metastases (13), as well as in other neurological condi-
tions including stroke (14), sub-arachnoid hemorrhages (SAHs)
(15), and silent cerebral infarcts (16). Bernstein et al. investigated
the psychometric properties of the MoCA in three diverse brain
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pathologies and concluded that it was reliable in detecting cogni-
tive dysfunction as well as having the benefit of not fatiguing the
patient (17). However, regardless of which cognitive screening tool
has the greatest sensitivity, the original purpose of these tools was
to detect global or generalized decline rather than domain-specific
cognitive deficits. Indeed, the need for domain-specific cognitive
tests for the brain tumor population was recently highlighted by a
study of glioma patients (6). In this study, a range of specific visu-
ospatial deficits were identified in right parieto-temporal gliomas
that were not present in patients with prefrontal tumors Thus, it
remains uncertain whether cognitive screening tools are sensitive
to identify mild and/or focal deficits in brain tumors (4, 12).
Neuropsychological evaluations are held to be the “gold stan-
dard” for assessment of cognitive functions in focal neurological
disorders like stroke (15, 18). However, evaluations differ in test
composition and can range from long and comprehensive, with a
fixed test battery, to brief and flexible, with tests chosen to assess
specific cognitive domains (19). One advantage of neuropsycho-
logical evaluation is the freedom to include tests that tap specific
cognitive functions, depending on tumor location and presenting
symptoms (4). On the other hand, the main criticism is the length
of assessment that can range from brief (1–2 h) to lengthy (8 h).
Length is a particular issue in brain tumor patients as physical and
mental fatigue has specifically been identified as a concern (12,
20). In fact, Olsen and colleagues (12) found a selection bias in
which patients were willing to complete a 4-h neuropsychological
assessment. In particular, they identified that those who completed
both the 4-h assessment and cognitive screening tests, tended to be
younger with a higher level of education, they obtained a higher
MoCA score and were on lower doses of medications. Thus, Olsen
and colleagues, like Papagno et al. (4), concluded that a brief and
well-tolerated CA is desirable, when diagnostic accuracy can be
maintained.
Neuropsychological evaluation has been compared to cognitive
screening tools. As noted above, Olsen and colleagues (12) com-
pared neuropsychological assessment to both the MMSE and the
MoCA. The MoCA showed greater sensitivity to cognitive dys-
function than the MMSE; however, the main conclusion was that
inclusion of a 4-h neuropsychological assessment was a significant
deterrent for participation. The MMSE and MoCA, compared to
neuropsychological assessment and return to work status, have
been investigated in patients following aneurysmal SAH (15). In
their study, 42% of patients were impaired on the MoCA, com-
pared to none on the MMSE, and the MoCA correlated with
domain-specific cognitive tests while the MMSE showed no asso-
ciation with specific tests. In addition, two MoCA items were
associated with return to work. The MoCA was concluded to be
more sensitive than the MMSE in SAH; however, it was not clear
that the MoCA had sufficient sensitivity when compared to the
neuropsychological assessment (15). Recently, a large retrospec-
tive study of acute stroke has unequivocally demonstrated that the
MoCA underestimated cognitive impairment, compared to a brief
1–2 h neuropsychological assessment (18).
The current study compared the MoCA cognitive screening
tool with a brief 1–1.5 h neuropsychological evaluation in primary
brain tumors. The neuropsychological evaluation comprised a CA
and mood and behavioral assessments as this is thought important
to fully characterize level of function and inform care plans (7).
The aim was to ascertain whether the MoCA is sufficiently sen-
sitive to detect cognitive impairment at an acute, post-resection
time point or whether a brief but domain-specific CA is necessary.
MATERIALS AND METHODS
PATIENTS
Thirty-six patients with primary brain tumors (low- or high-grade
gliomas, meningiomas) were recruited by the Brain Tumor Nurse
Practitioner (VB) from BrizBrain and Spine, The Wesley Hos-
pital, Brisbane, QLD, Australia. Ethical approval for the study
was granted by the UnitingCare and The University of Queens-
land Human Research Ethics Committees. Informed and written
consent was obtained from all patients. Inclusion criteria were
(1) confirmation of brain tumor ascertained by MRI and (2) all
patients underwent surgical resection prior to the investigation of
cognitive functions. The cognitive screening tool was administered
before the CA, which was completed in one testing session. The
third (3) inclusion criterion was that the cognitive screening tool
and CA were completed within the same week to minimize effects
due to timing of cognitive screening or assessment. Thus, due to
the latter, only 23 patients aged 18–69 years old were included.
The mean time between surgical resection and neuropsycholog-
ical evaluation was 2.1 months (SD= 3.1; see Table 1 for patient
characteristics). We note that 2.1 months is sufficient time to allow
for findings to be useful for neurorehabilitation (if available), plan-
ning for management of deficits for the patient and family/carers,
and to address any questions related to returning to community
roles at home or work.
COGNITIVE SCREENING
The MoCA (11) was used as the screening tool. Although it
was developed as a brief measure of global cognitive function,
it contains items that measure these cognitive domains: visu-
ospatial/executive function; naming; memory; language; abstrac-
tion; and attention. Specifically, the MoCA is scored out of 30
points comprising these items: brief trail making, cube copy, and
clock drawing (visuospatial/executive domain= 5 pts); animals
to name (naming domain= 3 pts); five words to recall (memory
domain= 5 pts); three brief attention tasks (attention domain= 6
pts); sentence repetition and word fluency (language domain= 3
pts); similarities (abstraction domain= 2 pts); time/place ques-
tions (orientation domain= 6 pts). A normal score is 26 or
above.
NEUROPSYCHOLOGICAL EVALUATION
Cognitive assessment
A brief but tailored CA was administered that was completed in 1–
1.5 h, depending on individual patient’s level of fatigue and ability.
The CA was devised based on neuropsychological assessment prin-
ciples and assessment of standard cognitive domains, detailed in
Cipolotti and Warrington (21). The cognitive tests were specifically
chosen based on Robinson’s recent lesion studies of brain tumor
and stroke patients with focal frontal and non-frontal lesions [e.g.,
Ref. (22, 23)]. A similar approach was adopted by Papagno and
colleagues (4) in their recent study of low-grade gliomas. Thus,
estimated pre-morbid level of intelligence was ascertained in a
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Table 1 | MoCA, demographic, and behavioral scores (mean±SD): all
patients and MoCA sub-groups (MoCA-Intact and MoCA-Impaired).
All (N =23) MoCA-Intact
(N =16)
MoCA-Impaired
(N =7)
MoCA score (/30) 26.52±2.11 27.63±1.15 24.00±1.53***
Age (M ±SD) 48.39±14.61 46.94±15.81 51.71±11.79
Gender (M:F) 16:7 12:4 4:3
Education 13.90±2.98 14.33±2.94 12.83±3.06
Pre-morbid estimated
intelligence (NART IQ)
104.13±10.35 103.56±10.24 105.43±11.30
Chronicity (months
post-surgery)
2.07±3.11 2.54±3.48 0.67±0.41
Tumor type
(WHO grade)
Meningioma 4 3 1
Oligodendroglioma (II) 5 4 1
Astrocytoma (II) 4 2 2
Oligodendroglioma (III) 1 1 0
Astrocytoma (III) 1 1 0
Glioblastoma
multiforme (IV)
8 5 3
Tumor location (L/R) 12/11 8/8 4/3
Frontal (L/R) 7/3 4/2 3/1
Temporal (L/R) 2/3 1/2 1/1
Parietal (L/R) 0/2 0/2 0/0
>1 lobe (L/R) 2/3 2/2 0/1
HADS anxiety (/21) 5.94±3.86 5.83±4.17 6.20±3.43
HADS depression (/21) 3.88±2.62 3.08±2.43 5.80±2.17*
Apathy Evaluation
Scale (/72)
49.20±15.41 50.86±16.17 45.33±14.05
NART, National Adult Reading Test; L, left; R, right; HADS, Hospital Anxi-
ety and Depression Scale. ***p<0.001, *p<0.05, MoCA-Intact compared to
MoCA-Impaired patients.
standard manner by administering the National Adult Reading
Test (NART) (24). To ascertain current level of cognitive function,
the CA comprised standard published neuropsychological tests
that focused on the following domain-specific areas of cognition:
(1) Abstract reasoning : non-verbal – Raven’s advanced progressive
matrices (25), verbal – Proverb Interpretation Test (26, 27); (2)
attention – Digit Span subtest from the Wechsler Adult Intelligence
Scale-III (28), Elevator Counting with Distraction from the Test
of Everyday Attention (29); (3) verbal and visual memory – Recog-
nition Memory Tests, Words, and Topography (30, 31); (4) visual
perception – Incomplete Letters Test from the Visual Object and
Space Perception Battery (32); (5) language – Graded Naming Test
(33), Word Comprehension – Synonyms Test (34); and (6) exec-
utive functions – phonemic word fluency (35), Hayling Sentence
Completion Test (36).
Mood and behavior assessment
As part of the neuropsychological evaluation, level of self-reported
anxiety, depression, and apathy were assessed using the Hospital
Anxiety and Depression Scale (HADS) (37) and the Apathy Eval-
uation Scale (AES) (38). A score on the HADS of 7 or below is in
the normal range with a score at or above 11 indicating significant
levels of anxiety or depression. The AES results in scores between
18 and 72, with higher scores indicating increased apathy and a
score of 41 suggested as the cut-off.
Analyses
The MoCA and domain-specific cognitive tests were administered
and scored in the standard and published manner. Patients were
classified as cognitively intact on the MoCA if they obtained a
score of≥26 or impaired if they scored<26 (11). For each individ-
ual cognitive test, patients were classified as cognitively impaired
if they scored <5th percentile (i.e., 5% cut-off), with an intact
performance ≥5% cut-off [for similar methodology, see Ref. (18,
39)]. For the Proverb Interpretation Test of verbal abstraction, an
impaired performance was a score of <5/8 [for scoring details, see
Ref. (24)].
Performance was analyzed in several ways. First, we calculated
a broad measure of impairment for both the MoCA and the CA.
For the MoCA, the number of patients impaired is reported. For
the CA, we calculated the number of patients impaired on any
test and also the number of cognitive domains each patient was
impaired in (i.e., 0–6 cognitive domains). Second, based on the
method adopted by Chan and colleagues for stroke patients (18),
we conducted two specific analyses: (1) MoCA-Intact patients were
investigated for impairment in each cognitive domain assessed by
the CA; and (2) Patients who scored the maximum points in each
of the MoCA-specified cognitive domains, irrespective of the over-
all MoCA score, were analyzed in terms of discrepancy between
this and performance on the domain relevant CA test. We also
analyzed whether the MoCA-Impaired patients were impaired in
at least one cognitive domain.
RESULTS
For the first broad measure, we found that 30.4% (7/23) of our
patients were impaired on the MoCA as they scored <26. A sum-
mary of the MoCA, demographic, and mood and behavior scores
for the whole group, and the MoCA-Intact and MoCA-Impaired
sub-groups, are contained in Table 1. As expected, the MoCA score
for the impaired group was significantly lower than the intact
group, t (21)= 6.31, p< 0.001. Apart from slightly higher self-
reported symptoms of depression by the MoCA-Impaired group
compared to the MoCA-Intact group, t (15)= 2.16, p< 0.05,
the two groups were well matched for age, gender, education,
pre-morbid intelligence, and chronicity (time since surgery; all
p> 0.05). Similarly, there was no difference between these two
groups in self-reported anxiety or apathy. With regard to symp-
toms of depression, we note that the mean of both groups is
in the “normal” range and not indicative of clinical or sub-
clinical depression. If we examine individual scores, one patient
in each group (MoCA-Intact and -Impaired) was in the abnor-
mal range. For anxiety, abnormal scores were obtained by three
patients in each group (MoCA-Intact and -Impaired). Finally,
both groups reported mildly elevated levels of apathy with a
number of patients in both groups above the suggested cut-
off (11 in the MoCA-Intact and 4 in the MoCA-Impaired
group), which may reflect the acute post-resection stage of
assessment.
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Table 2 | Domain-specific CognitiveTest Scores (mean±SD): all participants, MoCA sub-groups (MoCA-Intact and MoCA-Impaired), and
comparison statistic between MoCA sub-groups.
Cognitive domain/test All (N =23) MoCA-Intact (N =16) MoCA-Impaired (N =7) pValue
Abstract reasoning
Advanced progressive matrices (/12) 7.09±2.15 7.31±2.27 6.57±1.90 p=0.460
Proverb Interpretation Test (/8) 4.47±1.28 4.67±1.16 4.00±1.58 p=0.344
Memory
RMT words (/50) 45.91±4.51 46.19±4.52 45.29±4.79 p=0.670
RMT topography (/30) 22.57±6.33 23.40±6.24 20.50±6.63 p=0.356
Attention
Digit span total 17.00±5.14 17.00±4.45 17.00±6.99 p=1.00
Elevator counting+distraction (/10) 5.88±3.38 6.20±3.33 5.33±3.72 p=0.095
Language
Graded Naming Test (/30) 18.22±3.46 19.31±2.82 15.71±3.68∗ p=0.018
Synonyms (/50) 39.85±3.66 40.36±3.75 38.67±3.45 p=0.358
Visual perception
Incomplete letters (/20) 19.50±0.67 19.56±0.73 19.33±0.52 p=0.490
Executive function
Phonemic word fluency (FAS) 34.25±13.23 38.36±11.91 24.67±11.78∗ p=0.030
Hayling Test Overall Scaled Score (1–10, 6=Average) 3.52±2.47 3.63±2.36 3.29±2.87 p=0.769
Bold represents a significant finding. *p<0.05.
For the CA broad measure, 69.6% (16/23) of the patients
were impaired on at least one domain-specific cognitive test. The
means and SDs for the whole group, and the MoCA-Intact and
MoCA-Impaired sub-groups, are reported in Table 2. Overall,
there was no difference between sub-groups in performance on
9 of the 11 cognitive tests (i.e., p> 0.05), which supports specific
patterns of cognitive deficits rather than a generally lower perfor-
mance of the MoCA-Impaired patients. By contrast, the MoCA-
Impaired group performed significantly poorer on the Graded
Naming Test of language, t (21)= 2.567, p< 0.05, and the phone-
mic word fluency test that is sensitive to executive dysfunction,
t (21)= 2.363, p< 0.05. The number of cognitive domains each
patient was impaired in was as follows: 4/16 impaired in one
domain; 4/16 impaired in two domains; 6/16 impaired in three
domains; and 2/16 impaired in four domains. Thus, 75.0% of the
impaired patients were impaired on tests in at least two cognitive
domains.
For the specific measures based on Chan et al. (18), first we
investigated the 16 MoCA-Intact patients for impairment in each
cognitive domain assessed by the CA. Of these patients, 56.3%
were impaired in at least one of the six cognitive domains. The
percentage of MoCA-Intact patients impaired on domain-specific
cognitive tests is shown in Figure 1. The main cognitive domains
impaired for MoCA-Intact patients were abilities related to higher
level executive functions, including abstract reasoning, followed by
attention and memory. By contrast, language was only impaired
in <10% and no patient was impaired on the test of visual
perception.
For the second specific measure, we examined patients who
scored the maximum points in each of the MoCA-specified cog-
nitive domains, irrespective of the overall MoCA score. Based on
Chan et al. (18), we analyzed the discrepancy between this and
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FIGURE 1 | Cognitive assessment: MoCA-Intact participants impaired
in domain-specific cognitive tests.
performance on the domain relevant CA test. The number of
patients who scored full marks on each MoCA-specified domain,
were impaired on the relevant CA test and the negative predictive
values are reported in Table 3.
For the MoCA-Impaired patients, 100% were impaired in at
least one cognitive domain on the CA. Thus, when a patient
obtains an impaired score on the MoCA this fully predicts signif-
icant impairment in at least one domain on CA. By contrast, the
implications for cognitive function is less certain when a “normal”
MoCA score is obtained as the MoCA showed very poor negative
predictive value (0.44). Further, sensitivity for detecting cognitive
impairment is extremely poor (0.44) in our primary brain tumor
sample.
Frontiers in Oncology | Neuro-Oncology March 2015 | Volume 5 | Article 60 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Robinson et al. Cognitive assessment in brain tumors
Table 3 | Cognitive assessment performance and negative predictive
value for MoCA-specified domains.
MoCA-specified
domain
No. patients
scoring full
marks on MoCA
No. patients (%)
impaired on CA
Negative
predictive
value (NPV)
Visuospatial/executive 13 5 (38%) 0.62
Naming 21 3 (14%) 0.86
Memory 4 1 (25%) 0.75
Attention 13 4 (31%) 0.69
Language 7 3 (43%) 0.57
Abstraction 22 9 (41%) 0.59
DISCUSSION
In our unselected primary brain tumor sample, only 30.4% were
impaired on the MoCA cognitive screening tool. By contrast, for
the CA, 69.6% of patients were impaired on at least one domain-
specific cognitive test and, of these, 75% were impaired in at least
two cognitive domains. If we examine the MoCA-Intact patients,
more than half (56.3%) were impaired in at least one of the six
cognitive domains. Specifically, 50% of the MoCA-Intact patients
were impaired on tests of executive function, including abstrac-
tion, and a quarter of these patients were impaired in the domains
of attention and memory. The level of sensitivity of 0.44 for the
MoCA in our patients was far lower than for other neurological
disorders. For example, the sensitivity of the MoCA in an acute
stroke population was 0.82 (18) and, notably, assessments were
completed at comparable times post-stroke or tumor resection.
However, we note that the MoCA has been found useful in patients
with brain metastases (13) and it is reported to be adequate for
the detection of mild cognitive impairment in neurodegenerative
disorders such as Alzheimer’s and Parkinson’s disease [e.g., Ref.
(40)]. Nevertheless, the sensitivity of 0.44 of the MoCA for our
primary brain tumor population is extremely poor.
In light of this low detection rate of cognitive abnormalities, it
is noteworthy that the mean MoCA score of 26.5 for our tumor
patients is relatively high and indicative of mild global cognitive
impairment. This was also the case for our mood and behavioral
measures of anxiety, depression, and apathy. More specifically, the
“MoCA-Intact”group obtained a score almost identical to the nor-
mal controls reported by Nasreddine et al. (11) while the mean
score of 24 for the “MoCA-Impaired” group falls toward the top
of the “mild cognitive impairment” group. The overall “mild”
level of impairment on the MoCA in our sample differs from
the lower MoCA mean score of 22 in patients with brain metas-
tases (13). In fact, Olsen et al. suggested that the MoCA score
may be helpful in this population as patients with low MoCA
scores may be less likely to benefit from palliative whole-brain
radiotherapy while patients with high MoCA scores may toler-
ate more intensive interventions (13). Thus, for prognostic and
treatment purposes in brain metastases, the MoCA may be use-
ful. However, our results at a global level support the notion that
primary brain tumor-associated cognitive deficits are indeed mild
and/or focal and are hard to detect using global screening tools
like the MoCA.
For the 69.6% of patients impaired in at least one cognitive
domain on the CA, executive functions and abstract reasoning
were the most common domains impaired by far. In fact, 87.5%
of patients were impaired in these two domains and the remain-
ing two patients presented with a selective nominal aphasia. This
is followed by attention (43.8% impaired) and memory (37.5%
impaired). These cognitive domains being the most often impaired
is consistent with the findings of Tucha et al. (10) for frontal and
temporal tumor patients. Interestingly, of the two executive func-
tion tests, phonemic word fluency and the Hayling Test, 52.2%
of all patients were impaired on just one test, the Hayling Test,
which suggests that test choice is critical. With regard to mem-
ory, the MoCA does not assess visual memory and 21.7% of our
patients were impaired on our specific visual memory test. By
contrast, the intact performance of all our patients on our test
of visual perception does not reflect the finding of Shallice and
colleagues (6) of visuospatial deficits in right posterior tumor
patients. There are two possibilities for the apparent disparity.
One, our specific test of visual perception is not sensitive to mild
deficits. Two, our seven patients with right posterior tumors are
remarkably intact. Upon examination of individual patients, one
right temporal MoCA-Impaired and three right posterior MoCA-
Intact patients lost points on the MoCA-specified visuospatial
items. In addition, one of the MoCA-Intact patients presented
with a highly selective apperceptive amusia in the context of an
otherwise intact cognitive profile (41). This latter case, in addition
to the two patients with a selective nominal aphasia, highlight the
potential for any cognitive deficit to be specific and focal in brain
tumor patients, thus, necessitating freedom in test choice based on
symptoms and/or tumor location.
Notably, patients who performed well on MoCA-specified
domains were not always intact on the specific cognitive test,
similar to Chan et al.’s findings in acute stroke patients. This
is particularly so for the abstraction and executive/visuospatial
MoCA-specified domains that are assessed by one item each, both
clearly insensitive to our patients’ deficits. By contrast, the two
MoCA-specified domains that most closely resembled the CA
impairments were language and memory. In terms of language,
only 30.4% of patients scored full marks on the MoCA-specified
items that comprised a sentence repetition item (>10 words in
length) and a phonemic word fluency task. Of these two items,
phonemic word fluency was one of two standard cognitive tests
that MoCA-Impaired patients performed significantly poorer than
MoCA-Intact patients and it can be classed a test of executive func-
tion. If we examine naming ability, almost all patients obtained
full marks for the MoCA naming items, although 17.4% of all
patients were impaired on the standard Graded Naming Test. Very
few patients obtained full marks on the MoCA-specified memory
items although, as noted above, a main limitation of the MoCA is
that visual memory is not assessed.
The inclusion of all types of brain tumors in our study could
be argued to limit our findings. This is unlikely for two reasons.
First, in our study, patients with both meningiomas and gliomas
(high/low-grade) were in the MoCA-impaired group (see Table 1).
Secondly, in a recent study specifically investigating the effect of
etiology on cognitive performance in patients with focal frontal
lesion, once age and pre-morbid intelligence were accounted for,
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there were no significant differences between patients of dif-
ferent etiologies (stroke, meningioma, high/low-grade gliomas
(42). One caveat, however, is the practical implications of treat-
ments for different brain tumor types. For example, the timing
of a brief CA in patients with higher grade gliomas who pro-
ceed to receive initial radiation or chemotherapy at 2–6 weeks
post-resection, followed by a gap with no treatment and then
adjuvant chemotherapy (43), needs to be considered in specific
contexts. If a neuropsychologist is attached to an acute neurosur-
gical ward, then assessment prior to treatment can be included
in routine planned care. If this is unavailable, then an optimal
time would be in the gap between treatments, which would be
approximately 8–10 weeks post-resection. Findings from a brief
CA at either of these time points will be useful in further man-
agement, informing specific cognitive strategies/interventions and
for the patient to understand changes in thinking related to their
tumor.
In summary, the MoCA has extremely poor sensitivity to cogni-
tive impairment in our primary brain tumor sample, which means
that if a “normal” MoCA score is obtained, a CA is necessary. Even
if a patient is impaired on the MoCA, the severity may be under-
estimated and some areas of cognition are not assessed. In fact,
only one MoCA-specified domain showed even remotely similar
detection levels as a brief CA. A full discussion of other brief cog-
nitive screening tools (e.g., ACE-III; CogMed) is beyond the scope
of this preliminary study although we can speculate that similar
issues would be revealed. Thus, despite the limitations of our small
sample size, we strongly demonstrate that a brief and tailored CA
lasting only 1–1.5 h is necessary and possible for the detection
of cognitive impairments in primary brain tumor patients in the
acute phase post-surgery. This is not only important for progno-
sis and monitoring, but it is crucial for neurorehabilitation and
interventions (1, 2, 4). Moreover, mental deterioration, or fear of
this, was rated as one of the highest concerns of patients and car-
ers, contributing to quality of life (20). Our study suggests that
the critical cognitive domains to assess are executive functions
(initiation, suppression, abstraction), attention, memory (verbal
and visual), and language (naming and verbal fluency). Finally, we
highly recommend adopting the neuropsychological principle of
tailoring an assessment based on lesion location and presenting
symptoms.
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